secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123286
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences Q3 net loss $24M; cash $360M; positive interim TYRA-300 mUC data
--------------------------------------------------------------------------------

- Net loss $24.0M in Q3 2024 vs $21.2M in Q3 2023; R&D expense $22.7M, up from $19.3M.
- Cash, equivalents, and marketable securities $360.1M; runway through at least 2026.
- TYRA-300 interim data: at ≥90 mg QD, 6/11 (54.5%) mUC patients with FGFR3+ had confirmed PR; 100% disease control.
- FDA cleared IND for Phase 2 achondroplasia study (BEACH301); first child dosing expected Q1 2025.
- Appointed Doug Warner as Chief Medical Officer, effective September 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000095017024123286/0000950170-24-123286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000095017024123286/tyra-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer